Literature DB >> 26763731

Rheumatoid arthritis: Missed opportunities in the 2015 ACR guideline for RA treatment.

Ronald van Vollenhoven1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26763731     DOI： 10.1038/nrrheum.2015.181

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

1.  Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.

Authors:  T Möttönen; P Hannonen; M Leirisalo-Repo; M Nissilä; H Kautiainen; M Korpela; L Laasonen; H Julkunen; R Luukkainen; K Vuori; L Paimela; H Blåfield; M Hakala; K Ilva; U Yli-Kerttula; K Puolakka; P Järvinen; M Hakola; H Piirainen; J Ahonen; I Pälvimäki; S Forsberg; K Koota; C Friman
Journal:  Lancet       Date:  1999-05-08       Impact factor: 79.321

2.  Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.

Authors:  M Boers; A C Verhoeven; H M Markusse; M A van de Laar; R Westhovens; J C van Denderen; D van Zeben; B A Dijkmans; A J Peeters; P Jacobs; H R van den Brink; H J Schouten; D M van der Heijde; A Boonen; S van der Linden
Journal:  Lancet       Date:  1997-08-02       Impact factor: 79.321

3.  Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

Authors:  Ronald F van Vollenhoven; Roy Fleischmann; Stanley Cohen; Eun Bong Lee; Juan A García Meijide; Sylke Wagner; Sarka Forejtova; Samuel H Zwillich; David Gruben; Tamas Koncz; Gene V Wallenstein; Sriram Krishnaswami; John D Bradley; Bethanie Wilkinson
Journal:  N Engl J Med       Date:  2012-08-09       Impact factor: 91.245

4.  Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study.

Authors:  Merete Lund Hetland; Kristian Stengaard-Pedersen; Peter Junker; Tine Lottenburger; Torkell Ellingsen; Lis Smedegaard Andersen; Ib Hansen; Henrik Skjødt; Jens Kristian Pedersen; Ulrik Birk Lauridsen; Anders Svendsen; Ulrik Tarp; Jan Pødenphant; Gert Hansen; Hanne Lindegaard; Anselmo de Carvalho; Mikkel Østergaard; Kim Hørslev-Petersen
Journal:  Arthritis Rheum       Date:  2006-05

5.  Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.

Authors:  Björn Svensson; Annelies Boonen; Kristina Albertsson; Désirée van der Heijde; Catharina Keller; Ingiäld Hafström
Journal:  Arthritis Rheum       Date:  2005-11

6.  Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial).

Authors:  S M M Verstappen; J W G Jacobs; M J van der Veen; A H M Heurkens; Y Schenk; E J ter Borg; A A M Blaauw; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-05-22       Impact factor: 19.103

Review 7.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

Authors:  Jasvinder A Singh; Kenneth G Saag; S Louis Bridges; Elie A Akl; Raveendhara R Bannuru; Matthew C Sullivan; Elizaveta Vaysbrot; Christine McNaughton; Mikala Osani; Robert H Shmerling; Jeffrey R Curtis; Daniel E Furst; Deborah Parks; Arthur Kavanaugh; James O'Dell; Charles King; Amye Leong; Eric L Matteson; John T Schousboe; Barbara Drevlow; Seth Ginsberg; James Grober; E William St Clair; Elizabeth Tindall; Amy S Miller; Timothy McAlindon
Journal:  Arthritis Rheumatol       Date:  2015-11-06       Impact factor: 10.995

8.  Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis.

Authors:  Ronald F van Vollenhoven; Mikkel Østergaard; Marjatta Leirisalo-Repo; Till Uhlig; Marita Jansson; Esbjörn Larsson; Fiona Brock; Karin Franck-Larsson
Journal:  Ann Rheum Dis       Date:  2015-04-14       Impact factor: 19.103

9.  Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.

Authors:  Josef S Smolen; Paul Emery; Roy Fleischmann; Ronald F van Vollenhoven; Karel Pavelka; Patrick Durez; Benoît Guérette; Hartmut Kupper; Laura Redden; Vipin Arora; Arthur Kavanaugh
Journal:  Lancet       Date:  2013-10-26       Impact factor: 79.321

10.  Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.

Authors:  Karen Hambardzumyan; Rebecca Bolce; Saedis Saevarsdottir; Scott E Cruickshank; Eric H Sasso; David Chernoff; Kristina Forslind; Ingemar F Petersson; Pierre Geborek; Ronald F van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2014-05-08       Impact factor: 19.103
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.